Living With Cancer, a PBS Documentary, Will Air in September

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

MINNEAPOLIS--Living With Cancer: A Message of Hope, a conversation with some of the nearly 10 million US cancer survivors, debuts nationally on PBS, Friday, September 25, at 9:00 pm (check local listings).

MINNEAPOLIS--Living With Cancer: A Message of Hope, a conversation with some of the nearly 10 million US cancer survivors, debuts nationally on PBS, Friday, September 25, at 9:00 pm (check local listings).

Narrated by Anne Bancroft and filmed at the Mayo Clinic Cancer Center, Rochester, Minn, this 1-hour documentary recounts the experiences of cancer survivors, including a 5-year-old leukemia patient and her parents, a cardiologist with testicular cancer, and an ovarian cancer survivor who celebrates "the miracle" of her daughter’s birth. In addition, leading oncologists share new cancer research and provide an overview of causes and preventive steps to lower cancer risk.

The film is being presented on PBS by KTCA-TV, St. Paul/Minneapolis. It debuts on the eve of The March . . . Coming Together to Conquer Cancer, a national cancer awareness event sponsored by the National Coalition for Cancer Sur-vivorship and others. It takes place in Washington, DC, and other cities around the country on September 26.

Recent Videos
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.